Shares used in calculation of basic
and diluted net loss per share: 56,189 56,078 56,169 56,005
(1) Stock-based compensation
expenses included in operating
expenses amounted to approximately:
Research and development $560 $646 $3,005 $2,892
Selling, general and administrative 899 1,218 4,758 5,745
Restructuring and impairment charges -- -- 968 --
IDENIX PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)
(UNAUDITED)
December 31, December 31,
2007 2006
ASSETS
Cash and cash equivalents $48,260 $55,892
Marketable securities 39,862 71,251
Receivables from related party 11,196 12,035
Other current assets 4,401 8,427
Total current assets 103,719 147,605
Intangible assets, net 13,548 --
Property and equipment, net 15,461 17,448
Marketable securities, non-current 23,882 59,208
Other assets 3,930 4,204
Total assets $160,540 $228,465
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued expenses $21,809 $23,429
Deferred revenue, related party 8,372 13,490
Other current liabilities 553 527
Total current liabilities
'/>"/>
| SOURCE Idenix Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |